MDxHealth SA

MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, The Netherlands, Belgium, Spain, Poland, Italy, Rest of EU, and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2024 and the closing of a new debt facility with OrbiMed. Michael K.

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient's risk of developing cancer, disease progression, and response to prostate cancer therapies.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA (NASDAQ:MDXH ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Mark Massaro - BTIG Operator Good afternoon, ladies and gentlemen and welcome to the MDxHealth Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode.

MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Michael K.

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024.

Mdxhealth Announces Resignation of Board Member

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary fourth quarter and full year 2023 revenues and issued 2024 revenue guidance. The Company expects to report fourth quarter and full year 2023 revenues of approximately $19.4 and $70.2 million, respectively, with a year-end cash balance of $22.4 million, which reflects $2.3 million of non-operating and non-recurring cash use in the fourth quarter, primarily attributed to the transition to a sole listing on NASDAQ.

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance

NEWS RELEASE – REGULATED INFORMATION DECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET              MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – December 18, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces the completion of its transition to a single listing on Nasdaq. In accordance with prior announcements made by the Company and the corporate event notice issued by Euronext on December 6, 2023, the last trading day of the Company's ordinary shares (the "Shares") on the regulated market of Euronext Brussels was December 15, 2023.

MDxHealth Announces Completion of Transition to Single Listing on Nasdaq

NEWS RELEASE – REGULATED INFORMATION NOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – November 27, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces the completion of the mandatory exchange under the Company's American Depositary Shares ("ADSs") facility (the "Mandatory ADS Exchange"), the start of the transition to a single listing on Nasdaq, and details on the process for repositioning of the Company's shares from the Euronext Brussels trading system to the Nasdaq trading system. Mandatory ADS Exchange and transition to single listing on Nasdaq The Company announced on October 2, 2023, that its board of directors had determined that it is in the best interest of the Company, its investors and other stakeholders to consolidate all trading of the Company's securities on one exchange in the United States.

MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq

NEWS RELEASE November 14, 2023, 4PM ET/ 22:00 CET MDxHealth to Participate in the 35 th Annual Piper Sandler Healthcare Conference IRVINE, CA, and HERSTAL, BELGIUM – November 14, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in a fireside chat at the 35th Piper Sandler Healthcare Conference on Wednesday, November 29, 2023, at 9:00am ET.

MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference

MDxHealth SA (OTC:MXDHF) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Daniel Sammarco - TD Cowen Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Operator Good afternoon, ladies and gentlemen, and welcome to the MDxHealth Third Quarter 2023 Earnings Call. Before we begin, I would like to remind everyone that we will make forward-looking statements during today's call, whether in prepared remarks or during the Q&A session.

MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript

NEWS RELEASE – REGULATED INFORMATION 8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET             MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 IRVINE, CA, and HERSTAL, BELGIUM – November 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2023. Michael K.

MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023

NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET

MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation

NEWS RELEASE 25 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 Company to Host Conference Call with Live Q&A, November 8, 2023 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 25, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter and nine-month period ended September 30, 2023, after market close on Wednesday, November 8, 2023. Title: MDxHealth Presents Third Quarter 2023 Financial Results and Corporate Update Conference Call and Webcast Speakers: Michael K.

MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8

NEWS RELEASE - REGULATED INFORMATION October 20, 2023 , 4:00 PM EDT / 22:00 CET

Mdxhealth's New Share Capital Amount and New Number of Shares

MDxHealth SA Sponsored ADR (MDXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?

NEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 OCTOBER 2023, 4PM ET / 22:00 CET             MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL, BELGIUM – October 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary third quarter 2023 revenues, units, and cash position. For the third quarter ended September 30, 2023, the Company expects to report revenues of approximately $19.3 million, representing an increase of 73% over the same period last year and 15% versus the prior quarter; excluding GPS, Q3-2023 revenue increased by 45% over Q3-2022.

MDxHealth Reports Preliminary Q3-2023 Revenues

NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION OCTOBER 2, 2023, 4:00pm ET / 22:00 CET

MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting

NEWS RELEASE September 26 , 202 3 , 5 :00PM EDT / 23:00 CET

Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer

MDxHealth SA (OTC:MXDHF) Q2 2023 Earnings Call Transcript August 23, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Andrew Brackmann - William Blair Jason Bednar - Piper Sandler Thomas Vranken - KBC Securities Francois Brisebois - Oppenheimer & Co Operator Greetings, and welcome to MDxHealth's 2023 Q2 and Midyear Earnings Call. [Operator Instructions].

MDxHealth SA (MXDHF) Q2 2023 Earnings Call Transcript

MDxHealth SA Sponsored ADR (MDXH) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.70 per share a year ago.

MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue Estimates

NEWS RELEASE – REGULATED INFORMATION 23 AUGUST 202 3 , 4:00PM EDT / 22:00 CET

MDxHealth Reports Q2 and Half Year 2023 Results

NEWS RELEASE 10 AUGUST 202 3 , 4 PM ET / 22:00 CET

MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23

Cigna

Expansion of coverage with Cigna now includes full menu of Company's precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage.

Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth's Select mdx for Prostate Cancer Test

NEWS RELEASE - REGULATED INFORMATION                 30 June 2023 , 10:00 p.m. CE S T

News for MDxHealth SA Stock (MDXH)